Connect Biopharma Holdings (CNTB) Revenue (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Revenue for 3 consecutive years, with $169000.0 the latest figure, recorded in Q1 2026.

• Quarterly Revenue changed N/A year-over-year to $169000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $233000.0 (changed N/A YoY) and the FY2025 annual result came in at $64000.0, down 99.75% from the prior year.
• Revenue improved to $169000.0 in Q1 2026 per CNTB's latest filing, from $16000.0 in the prior quarter.
• Over the last five years, Revenue for CNTB reached as high as $1.2 million in Q3 2024 and fell as low as $16000.0 in Q3 2025.
• A 3-year average of $430000.0 and a median of $169000.0 in 2026 frame the typical range for Revenue.
• The largest YoY upside for Revenue was 98.69% in 2025 against a maximum downside of 98.69% in 2025.
• Year by year, Revenue stood at $698000.0 in 2024, then tumbled by 97.71% to $16000.0 in 2025, then surged by 956.25% to $169000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $169000.0, $16000.0, and $48000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.